In August, the Department of Health and Social Care (DHSC) asked pharmaceutical companies to hold a minimum of six weeks extra of supply of medicines ‘over and above their business as usual operational buffer stock’ in the event of a no-deal Brexit.
While some people welcomed the initiative, others argued that more needs to be done to safeguard products access and patient safety given the uncertainty around the availability of medicines post-Brexit.
The Pharmacist’s reporter Léa Legraien spoke to four pharmacy experts about how the Government’s stockpiling plans could affect the sector. Listen to the podcast below to find out what they had to say.
For more on how community pharmacy could be affected by Brexit, see here.
What do you think? Tweet us your views @Pharmacist_News